Research ArticleHuman Studies
In Vivo Use of a Radioiodinated Somatostatin Analogue: Dynamics, Metabolism, and Binding to Somatostatin Receptor-Positive Tumors in Man
Willem H. Bakker, Eric P. Krenning, Wout A. Breeman, Peter P. M. Kooij, Jean-Claude Reubi, Jan W. Koper, Marion de Jong, Johannes S. Laméris, Theo J. Visser and Steven W. Lamberts
Journal of Nuclear Medicine June 1991, 32 (6) 1184-1189;
Willem H. Bakker
Eric P. Krenning
Wout A. Breeman
Peter P. M. Kooij
Jean-Claude Reubi
Jan W. Koper
Marion de Jong
Johannes S. Laméris
Theo J. Visser
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
In Vivo Use of a Radioiodinated Somatostatin Analogue: Dynamics, Metabolism, and Binding to Somatostatin Receptor-Positive Tumors in Man
Willem H. Bakker, Eric P. Krenning, Wout A. Breeman, Peter P. M. Kooij, Jean-Claude Reubi, Jan W. Koper, Marion de Jong, Johannes S. Laméris, Theo J. Visser, Steven W. Lamberts
Journal of Nuclear Medicine Jun 1991, 32 (6) 1184-1189;
In Vivo Use of a Radioiodinated Somatostatin Analogue: Dynamics, Metabolism, and Binding to Somatostatin Receptor-Positive Tumors in Man
Willem H. Bakker, Eric P. Krenning, Wout A. Breeman, Peter P. M. Kooij, Jean-Claude Reubi, Jan W. Koper, Marion de Jong, Johannes S. Laméris, Theo J. Visser, Steven W. Lamberts
Journal of Nuclear Medicine Jun 1991, 32 (6) 1184-1189;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
- Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas
- Locoregional Delivery of Adenoviral Vectors
- Oral Versus Intravenous Administration of Lysine: Equal Effectiveness in Reduction of Renal Uptake of [111In-DTPA]Octreotide
- Somatostatin Receptors in Malignant Lymphomas: Targets for Radiotherapy?
- 64Cu-TETA-Octreotide as a PET Imaging Agent for Patients with Neuroendocrine Tumors
- Radioiodination via D-Amino Acid Peptide Enhances Cellular Retention and Tumor Xenograft Targeting of an Internalizing Anti-Epidermal Growth Factor Receptor Variant III Monoclonal Antibody